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Open access under CC BYAim: IL-18 is hypothesized to destabilise atherosclerotic plaques, leading to thrombotic events and epi-
demiologic studies suggest that IL-18 may increase risk of CHD or CVD. We examined prospective asso-
ciations between levels of serum IL-18 and new CHD and stroke events in older men and women from a
general population.
Methods: A case-control study was nested within a prospective cohort of men and women aged 60–
79 years recruited from general practices in 25 British towns in 1998–2000 and followed-up for 7.5 years
for fatal and non-fatal MI and stroke. Baseline IL-18 was measured in stored serum samples of incident
cases of MI (n = 364) or stroke (n = 300) and two controls per case.
Results: Geometric mean IL-18 levels were higher among the 364 MI cases than the 706 controls;
417.84 pg/mL (IQR 316.25, 537.44) compared to 386.90 pg/mL (IQR 296.54, 482.33), p(differ-
ence) = 0.002. IL-18 was positively associated with adverse lipid and inﬂammatory proﬁles. Men and
women in the top third of baseline IL-18 levels had an age and sex-adjusted odds ratio (OR) for MI of
1.31 (95%CI 0.92, 1.85) compared with those in the lowest third; this attenuated to 1.05 (95%CI 0.72,
1.53) after additional adjustment for established vascular and inﬂammatory risk factors. Each doubling
of IL-18 level was associated with an increased OR for MI 1.34 (95%CI 1.04, 1.72), which was attenuated
on adjustment for established vascular and inﬂammatory risk factors; 1.09 (95%CI 0.83, 1.44). Geometric
mean IL-18 levels did not differ between stroke cases and controls. The OR for stroke associated with the
highest compared to the lowest tertile of IL-18 was 1.24 (95%CI 0.84, 1.84). Results for MI and stroke did
not differ by presence of pre-existing CVD, gender or age.
Conclusions: Circulating IL-18 levels were strongly associated with a range of established and novel risk
factors but were not independently associated with risk of MI or stroke in our study.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Inﬂammation plays an important role in atherosclerosis and
several acute phase reactant proteins are associated with elevated
risk of cardiovascular disease (CVD). Interleukin 18 (IL-18) is a pro-
inﬂammatory cytokine which is highly expressed in atherosclerotic
plaques (mainly in plaque macrophages) and is detected in higher
levels in unstable than stable plaques [1]. IL-18 is thought to con-
tribute to destabilisation of atherosclerotic plaques, leading toeart Study, UCL Dept. Primary
Rowland Hill Street, London
4 20 7794 1224.
-NC-ND license.thrombotic events [1,2]. Plaque rupture is important in both CHD
and in the commonest type of stroke in older persons, athero-
thrombotic stroke. We recently conducted a meta-analysis of
twelve prospective epidemiologic studies of IL-18 and onset of cor-
onary heart disease (CHD) or CVD and found that higher levels of
IL-18 were associated with onset of CHD: participants in the top
third of baseline IL-18 levels had approximately 64% increased risk
of CHD, which attenuated to 34% after additional adjustment for
established risk factors and inﬂammatory markers [3]. Associations
did not differ appreciably between IL-18 and CHD alone or com-
bined endpoints including CVD.
To date most studies of IL-18 and CHD or stroke are of middle
aged adults, only three of the studies in the meta-analysis were
of populations with an average age over 65 years at study entry.
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importance of established risk factors such as blood pressure and
cholesterol are attenuated at older age [4,5], the relative impor-
tance of inﬂammatory markers in CVD aetiology may be height-
ened. Alongside possible changes in the aetiology of CVD in older
age groups, levels of circulating inﬂammatory markers increase
with age, as do levels of subclinical vascular disease and the num-
ber of co-morbidities associated with inﬂammation. Studies of
composite CVD endpoints including stroke together with other
CHD events ﬁnd evidence that IL-18 is associated with raised risk
of CVD [6,7] but fewer studies have speciﬁcally investigated the
role of IL-18 in the onset of stroke. Three studies including patients
from high risk groups (with history of stroke or CVD risk factors),
did not ﬁnd evidence that IL-18 was associated with risk of stroke
[8–10].
We therefore examined prospective associations between IL-18
and MI and stroke in a case-control study of older men and women,
aged 60–79 years at baseline, nested in two cohorts followed-up
for up to 8.5 years for incident CVD events. We examined whether
IL-18 was independently associated with MI or stroke in men and
women in the general population, and also whether the associa-
tions varied by age, gender and presence of pre-existing CVD. We
also examined whether any associations were mediated by other
inﬂammatory markers implicated in CVD.
2. Materials and methods
In 1998–2000, 4252 men from a single General Practice in each
of 24 British towns who were already taking part in a prospective
study of cardiovascular disease attended for follow-up measure-
ments at the age of 60–79 years (response rate 77%) [11]. In
1999–2001, a parallel study of 4286 women of the same age and
in the same Practices was established, with the addition one more
town (Bristol), response rate 60% [12]. All subjects provided writ-
ten informed consent to the investigation and ethical approval
was provided by relevant local research ethics committees. Near
identical study protocols were used. In both studies, nurses admin-
istered questionnaires, and women self-completed a separate addi-
tional detailed questionnaire. Pre-existing CVD was deﬁned from
validated reports from General Practitioner, or self-report of MI
or stroke at any questionnaire between 1978–80 and 1998–2000
in men and in the baseline questionnaire (1999/2001) in women
[12]. Data on cigarette smoking, alcohol consumption, physical
activity, own longest-held occupation (or husband’s occupation
for non-married women, coded using the Registrar General’s clas-
siﬁcation) were self-reported. Region of residence was recorded for
women in 1998–2001 and for men at the start of their follow-up in
1978–80. Nurses made physical measurements (weight, height,
seated blood pressure and FEV1), recorded an ECG and collected
fasting venous blood samples, from which serum was stored at
670 C for subsequent analysis of cholesterol, triglycerides,
haemostatic and inﬂammatory markers as described elsewhere
[11–14]. IL-18 (pg/mL) was measured from stored frozen serum
samples by researchers blinded to case control status using
enzyme-linked immunosorbent assays (R&D systems, Abingdon,
UK) according to the manufacturer’s instructions. Inter- and in-
tra-assay coefﬁcients of variation were 10.4% and 5.6%. IL-18 was
measured twice in 158 subjects over a 4 year interval, in 1996
and 2000 to enable intra-individual comparisons of values over
time [15].
Participants were followed-up for 6.25–8.5 years for mortality
and cardiovascular morbidity, with a follow up loss of <2%. Fatal
cases were ascertained through National Health Service Central
Registers from a death certiﬁcate: ICD-9 codes 410–414 for MI
and ICD-9 codes 430–438 for stroke, indicating deaths with cere-
brovascular disease as the underlying cause. Non-fatal MI or strokewas diagnosed using World Health Organisation diagnostic criteria
[16] based on validated reports from General Practitioners, supple-
mented by regular reviews of General Practice records [11,12].
We established a nested case-control study based on all 394
CHD cases occurring between February 1998 and June 2006 in
men and between April 1999 and September 2007 in women. A to-
tal of 788 controls ‘‘frequency matched’’ to cases on town of resi-
dence, gender and age in 5-year bands were randomly selected
from among subjects who had survived to the end of the study per-
iod free from incident CHD. Similarly a separate nested case control
study in 324 cases of stroke and 648 controls was established. In
the sample with complete data (n = 895), there were 299 MI cases,
from which we would have had 80% power to detect a relative risk
of 1.67 in the top tertile of IL-18 compared to the bottom tertile, at
the 5% statistical signiﬁcance level. From 235 cases of stroke, sim-
ilarly we would have had 80% power to detect a relative risk of
1.79, assuming 2 controls per case.2.1. Statistical analyses
Highly skewed variables were natural log transformed as neces-
sary. Means and standard deviations of baseline characteristics of
cases and controls aged 60–79 years were calculated. Continuous
variables were adjusted for gender, baseline region of residence
and age at examination. Distributions of categorical variables were
examined. Tertiles of IL-18 were deﬁned in the MI control sample.
Associations between IL-18 tertiles and covariates were examined
using one way ANOVA. Established risk factors were selected a pri-
ori and the novel inﬂammatory and haemostatic risk markers were
selected on the basis that they had been reported elsewhere to be
associated with MI and stroke. Unmatched logistic regression anal-
yses were used to examine associations between IL-18 tertiles and
MI. Models were adjusted for (i) gender, age and region of resi-
dence, (ii) established CHD risk factors ﬁtted as continuous vari-
ables (BMI, systolic and diastolic blood pressure, triglycerides,
total and HDL cholesterol) and the following categorical variables;
smoking (‘‘current’’, ‘‘ex-smoker’’ or ‘‘never smoker’’), alcohol use
(‘‘1–2 drinks/day’’ or ‘‘other’’) physical activity (‘‘more than 3 h of
moderate/vigorous activity per week’’ or ‘‘less’’), history of diabetes
(‘‘present’’ or ‘‘absent’’) (iii) novel risk factors (natural log trans-
formed CRP and IL-6). Linear regression was used to model the
association between risk of MI and continuous IL-18 (log2 transfor-
mation) in order to assess the effect of a doubling of IL-18 level on
risk of MI. Differences in the IL-18-MI or stroke associations were
tested using likelihood ratio (LR) tests for interactions with age,
gender and pre-existing CVD (MI or stroke). Rosner’s method was
used to calculate regression dilution ratios on a subset of men with
repeated IL-18 measurements, using a linear regression model of
the repeat measurement predicted by the ﬁrst measurement [17]3. Results
3.1. MI
IL-18 data were available for 364 of 394 MI cases and for 706 of
788 controls. Cases were aged on average 70.9 years, predomi-
nantly male (73%) and 45% were in non-manual occupations
(Table 1). Cases differed from controls in having a higher preva-
lence of pre-existing CVD and diabetes, more current smokers,
fewer drinkers of 1–2 units of alcohol/day and had lower levels
of physical activity (Table 1, all p < 0.02). Cases had higher SBP
and lower FEV1 but similar BMI and DBP to controls. Cases had less
favorable lipid, inﬂammatory and metabolic marker proﬁles.
Geometric mean IL-18 levels were higher among the 364 MI cases
Table 1
Baseline characteristics (age 60–79) of the MI case and control populations: mean (SD) unless otherwise speciﬁeda.
MI cases (n = 364) MI controls (n = 706) Difference (p value)
Demographic/questionnaire
Age (years) 70.87 (5.47) 70.83 (5.47) Matched
Male, n(%) 267 (73.4) 512 (72.5) Matched
Northern region of residence, n(%)b 151 (41.5) 291 (41.2) Matched
Non-manual occupation, n(%)b 154 (44.7) 323 (47.9) 0.351
Prior evidence of CVD, n(%) 109 (30.0) 119 (16.9) <0.001
History of diabetes, n(%) 66 (18.1) 75 (10.6) 0.001
1–2 alcoholic drinks/day, n(%) 127 (37.9) 301 (46.2) 0.013
Current smoker, n(%) 75 (20.6) 94 (13.3) 0.002
Physical activity (inactive/occasional), n(%) 233 (66.6) 397 (58.8) 0.016
Physical measurements
Body Mass Index (kg/m2)c,e 27.11 (4.26) 27.03 (3.97) 0.833
Systolic blood pressure (mm/Hg)c,d,e 153.84 (27.37) 148.58 (24.09) 0.001
Diastolic blood pressure (mm/Hg)c,d,e 83.75 (12.14) 83.22 (11.50) 0.482
FEV1 (L/min)c,e,g 2.15 (0.55) 2.23 (0.60) 0.032
Lipids/metabolic markers
Total cholesterol (mMol/L) 6.25 (1.23) 6.08 (1.07) 0.020
HDL cholesterol (mMol/L) 1.32 (0.33) 1.42 (0.36) <0.001
Triglyceride (mMol/L)c,d,f 1.80 (1.31, 2.39) 1.58 (1.13, 2.09) <0.001
Insulin (mU/L)c,d,f 9.54 (6.04, 13.97) 8.14 (5.57, 11.23) <0.001
Glucose (mMol/L)c,d,f 6.18 (5.35, 6.39) 5.82 (5.31, 6.11) <0.001
Inﬂammatory and hemostatic markers
IL-18(pg/mL)c,f 417.84 386.90 0.002
(316.25, 537.44) (296.54, 482.33)
C-Reactive Protein (mg/L)c,f 2.41 (1.06, 5.53) 1.77 (0.89, 3.60) <0.001
IL-6(pg/ml)c,d,f 2.99 (1.93, 4.08) 2.43 (1.61, 3.44) <0.001
Fibrinogen(g/L)c,d,f 3.46 (3.04, 3.95) 3.27 (2.85, 3.77) <0.001
White cell count (^109/L)c,d,f 7.28 (6.02, 8.74) 6.81 (5.67, 7.97) <0.001
a Case-control sample is maximum available.
b Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.
c Adjusted for gender, age at survey and region of residence (Scotland, North, Midlands and South).
d Adjusted for time of day.
e Adjusted for nurse number.
f Analysed as natural log transformed variable, geometric mean (IQR) reported on original scale.
g Adjusted for height squared.
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387 pg/mL (IQR 297, 482), p(no difference) = 0.002 (Table 1).
3.2. Stroke
IL-18 data were available for 300 of 324 cases and 590 of 648
controls. Cases were aged on average 71.3 years, were predomi-
nantly male (64%) (Table 2). Cases differed with respect to controls
in having higher prevalence of pre-existing CVD and more smokers
(p < 0.002). Cases had higher blood pressure and lower FEV1 but
similar BMI. Cases had similar lipid proﬁle, except for lower total
cholesterol. Cases had higher IL-6 and white blood cell count, but
they were similar to controls in respect to other inﬂammatory
and haemostatic markers (Table 2). Geometric mean IL-18 levels
did not differ signiﬁcantly between the 300 cases and the 590 con-
trols; 406 pg/mL (IQR 311, 532) compared to 389 pg/mL (IQR 300,
492) p(no difference) = 0.13 (Table 2).
3.3. Baseline correlates of IL-18
Table 3 summarizes the associations between IL-18 and cardio-
vascular risk factors across thirds of the MI control population (the
larger control population). Associations in the stroke control popu-
lation were similar (Web Table 1), unless noted below. IL-18 levels
were higher in men and in subjects with diabetes but did not vary
with age, social or behavioral factors, FEV1, BP or total cholesterol.
IL-18 was positively associated with BMI, triglycerides and inver-
sely associated with HDL cholesterol. Correlations between log
IL-18 and covariates were all r < 0.25 (e.g. in the MI control popu-
lation r = 0.23 for HDL p < 0.001; r = 0.20 for log insulin, p < 0.05;
r = 0.16 for t-PA p < 0.001; r = 0.13 for log CRP, p = 0.02 and r = 0.10for log IL-6, p = 0.20). Weak inverse associations with social class
and positive associations with cigarette smoking, insulin and glu-
cose did not reach conventional levels of statistical signiﬁcance
in the MI control population, but did in the stroke control popula-
tion. IL-18 was positively associated with CRP, IL-6, ﬁbrinogen,
plasma viscosity, Fibrin D-dimer, Von Willebrand Factor and tissue
plasminogen activator. Positive associations with white blood cell
count and Factor VIII only reached statistical signiﬁcance in the
stroke control sample.3.4. Associations between IL-18 and MI
Table 4 summarizes the associations between MI and tertiles of
IL-18. In Model 1 (adjusted for gender, age and region of residence),
the odds ratio (OR) for MI associated with the highest compared to
the lowest tertile of IL-18 (T3 vs T1) was 1.31 (95%CI 0.92, 1.85) and
there was no strong statistical evidence of a linear trend in ORs
across the three groups (p = 0.13). The ORs were attenuated on
adjustment for established risk factors (Model 2, smoking, alcohol,
physical activity, history of diabetes, BMI, systolic and diastolic
blood pressure, total and HDL cholesterol): T3 vs T1: 1.09 (95%CI
0.75, 1.58). Further adjustment for CRP and IL-6 (Model 3) had a
small attenuating effect: T3 vs T1 OR 1.05 (95%CI 0.72, 1.53). Each
doubling of IL-18 level was associated with increased risk of MI
(Model 1); 1.34 (95%CI 1.04, 1.72), however, this was attenuated
to the null on adjustment for established risk factors and other
inﬂammatory markers CRP and IL-6 (Model 3); 1.09 (95%CI 0.83,
1.44).
We conducted a sensitivity analysis to see whether the associ-
ations differed in participants without any pre-existing MI or
stroke compared to those with pre-existing disease. In stratiﬁed
Table 2
Baseline characteristics (age 60–79) of the stroke case and control populations: mean (SD) unless otherwise speciﬁeda.
Stroke cases (n = 300) Stroke controls (n = 590) Difference (p value)
Demographic/questionnaire
Age (years) 71.32 (5.33) 71.34 (5.26) Matched
Male, n(%) 191 (63.7) 372 (63.1) Matched
Northern region, n(%)b 107 (35.7) 221 (37.5) Matched
Non-manual occupation, n(%)b 123 (46.4) 259 (46.9) 0.679
Prior evidence of CVD, n(%) 84 (28.0) 88 (14.9) <0.001
History of diabetes, n(%) 42 (14.0) 72 (12.2) 0.448
1–2 alcoholic drinks/day, n(%) 105 (38.5) 210 (38.3) 0.953
Current smoker, n(%) 52 (17.3) 57 (9.7) 0.002
Physical activity (inactive/occasional), n(%) 196 (70.8) 380 (67.0) 0.273
Physical measurements
Body Mass Index (kg/m2)c,e 27.06 (4.36) 27.11 (4.09) 0.875
Systolic blood pressure (mm/Hg)c,d,e 154.19 (25.07) 149.18 (24.23) 0.004
Diastolic blood pressure (mm/Hg)c,d,e 84.80 (12.59) 82.35 (11.18) 0.003
FEV1 (L/min)c,e,g 2.09 (0.57) 2.23 (0.53) <0.001
Lipids/metabolic markers
Total cholesterol (mMol/L) 6.13 (1.22) 6.31 (1.17) 0.025
HDL cholesterol (mMol/L) 1.42 (0.39) 1.42 (0.36) 0.839
Triglyceride (mMol/L)c,d,f 1.65 (1.11, 2.32) 1.69 (1.23, 2.29) 0.473
Insulin (mU/L)c,d,f 8.88 (5.62, 12.99) 8.26 (5.23, 11.58) 0.136
Glucose (mMol/L)c,d,f 6.03 (5.29, 6.17) 5.87 (5.29, 6.11) 0.095
Inﬂammatory and hemostatic markers
IL-18 (pg/ml)c,f 406.34 (310.50, 531.77) 389.20 (300.17, 491.64) 0.131
C-Reactive Protein (mg/L)c,f 2.12 (1.04, 4.28) 1.92 (0.91, 4.16) 0.217
IL-6(pg/ml)c,d,f 2.85 (1.88, 4.13) 2.57 (1.65, 3.55) 0.028
Fibrinogen(g/L)c,d,f 3.35 (2.95, 3.84) 3.28 (2.88, 3.70) 0.139
White cell count (^109/L)c,d,f 7.24 (6.12, 8.57) 6.91 (5.79, 8.22) 0.017
a Case control sample is maximum available n = 890.
b Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.
c Adjusted for gender, age at survey and region of residence (Scotland, North, Midlands and South).
d Adjusted for time of day.
e Adjusted for nurse number.
f Analysed as natural log transformed variable, geometric mean (IQR) reported on original scale.
g Adjusted for height squared.
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MI (Table 4). A likelihood ratio (LR) test for interaction found no
evidence for difference between the two groups, p = 0.63. Gender
differences in associations between tertiles of IL-18 and MI were
tested and none were observed (LR test p = 0.67). Furthermore,
there was no evidence that the association between IL-18 and MI
varied by age (LR test p = 0.99).
3.5. Associations between IL-18 and stroke
Table 5 summarizes the associations between tertiles of IL-18
and stroke, in Model 1 (adjusted for gender, age and region of res-
idence), the OR for stroke associated with the highest compared to
the lowest tertile of IL-18 T3 vs T1 was 1.24 (95%CI 0.84, 1.84) and
there was no strong evidence of a linear trend across the three
groups (p = 0.29). There was no strong evidence of an association
between continuous IL-18 and stroke; the OR for a doubling of
IL-18 was 1.26 (95%CI 0.84, 0.89), Model 1. A sensitivity analysis
stratiﬁed by presence of prior CHD or stroke (Table 5), conﬁrmed
the results of the main analysis; no associations between IL-18
and stroke were observed in either the sample with pre-existing
disease or without pre-existing disease, LR test for interaction,
p = 0.38). Gender differences in associations between tertiles of
IL-18 and stroke were tested and none were observed (LR test
p = 0.84). Additionally, there was no evidence that the association
between IL-18 and stroke varied by age (LR test p = 0.54).
3.6. Regression dilution
Using Rosner’s method a regression dilution ratio of 0.71 (95%CI
0.61, 0.81) for IL-18 was calculated in a subset of 158 men withIL-18 levels measured 4 years apart [17]. The OR of MI among
men in the top third of IL-18 compared with the lowest third, ad-
justed for age and vascular risk factors (Model 3) 1.09 (95%CI 0.75,
1.58), was 1.13 (95%CI 0.67, 1.90) after correction for regression
dilution. The equivalent OR for strokes were 1.07 (95%CI 0.71,
1.61) and 1.10 (95%CI 0.62, 1.96) after correction for regression
dilution.
4. Discussion
In this nested case-control study, set within a prospective pop-
ulation-based cohort of 60–79 year old women and men, higher
serum IL-18 levels were associated with higher levels of other
inﬂammatory markers (CRP, IL-6, ﬁbrinogen and white cell count),
hemostatic markers (plasma viscosity, factor VIII, ﬁbrin D-dimer,
Von Willebrand factor and t-PA), with established cardiovascular
risk factors lipids (blood pressure and lipids) and also health
behaviors (cigarette smoking, participating in low levels of physi-
cal activity and being a non-drinker or a heavy drinker). Baseline
IL-18 levels were not associated with elevated risk of MI at conven-
tional levels of statistical signiﬁcance, consistent with some but
not all previous studies. The absence of association between IL-
18 and stroke over the follow-up period is in keeping with existing,
albeit sparse literature about IL-18 and stroke.
4.1. Strengths and weaknesses
The study beneﬁts from validated data about MI and stroke
events and has comprehensive data on a wide range of established
and novel cardiovascular risk factors. However, we were unable to
distinguish between subtypes of stroke, although we expect the
Table 3
Association between IL-18 (tertiles) and cardiovascular risk factors in the MI control sample (n = 706).
Low (95–324 pg/ml) n = 239 Medium (325–450 pg/ml) n = 232 High (451–2500 pg/ml) n = 235 Trend p-valuea
Demographic/questionnaire
Age (years) 70.70 70.97 70.82 0.801
Male, n(%) 143 (59.8) 181 (78.0) 188 (80.0) <0.001
Northern region, n(%)b 103 (43.1) 98 (42.2) 90 (38.3) 0.290
Non-manual occupation, n(%)b 114 (50.2) 111 (49.6) 98 (43.8) 0.170
Evidence of CVD, n(%) 40 (16.7) 35 (15.1) 44 (18.7) 0.566
History of diabetes, n(%) 18 (7.5) 25 (10.8) 32 (13.6) 0.033
1–2 alcoholic drinks/day, n(%) 94 (44.8) 105 (48.2) 102 (45.5) 0.882
Current smoker, n(%) 26 (10.9) 32 (13.8) 36 (15.4) 0.150
Physical activity (inactive/occasional), n(%) 131 (58.2) 127 (56.2) 139 (62.1) 0.410
Physical measurements
Body Mass Index (kg/m2)c,e 26.51 26.90 27.69 0.002
Systolic blood pressure (mm/Hg)c,d,e 148.02 148.49 149.14 0.621
Diastolic blood pressure (mm/Hg)c,d,e 82.62 83.72 83.31 0.530
FEV1 (L/min)c,e,g 2.27 2.23 2.18 0.134
Lipids/metabolic markers
Total cholesterol (mMol/L) 6.12 6.05 6.07 0.608
HDL cholesterol (mMol/L) 1.52 1.42 1.32 <0.001
Triglyceride (mMol/L)c,d,f 1.44 1.57 1.75 <0.001
Insulin (mU/L)c,d,f 7.18 8.01 9.36 0.094
Glucose (mMol/L)c,d,f 5.76 5.83 5.88 0.235
Inﬂammatory and hemostatic markers
C-Reactive Protein (mg/L)c,f 1.59 1.74 2.01 0.024
IL-6(pg/ml)c,d,f 2.25 2.39 2.56 0.031
Fibrinogen(g/L)c,d,f 3.22 3.22 3.37 0.051
White cell count (^109/L)c,d,f 6.94 6.78 6.74 0.250
Plasma viscosity (mPa s)c,d 1.29 1.28 1.30 0.044
Factor VIII (IU/dL)c 142.04 142.18 144.99 0.338
Fibrin D-dimer (ng/ml)c,f 80.43 101.78 108.55 <0.001
Von Willebrand factor (IU/dL)c 141.45 144.09 155.66 0.001
t-PA (ng/ml)c,d 9.83 10.18 10.95 0.002
a Sample (n = 706) MI controls with IL-18 value. Trend test adjusted for age, gender, region of residence.
b Reported in 1978–1980 (age 40–59 years) for men and in 1998–2000 (age 60–79 years) for women.
c Adjusted for age at survey and region of residence (Scotland, North, Midlands and South).
d Adjusted for time of day.
e Adjusted for nurse number.
f Geometric mean, p value from linear regression with ln(variable).
g Adjusted for height squared.
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and lacunar strokes, as atherothrombotic stroke is the commonest
type in older adults. IL-18 levels were measured using commercial
kits frequently utilized in other epidemiological studies of IL-18
[3]. Whilst cross-sectional and case-control studies cannot exclude
reverse causality, the nested case-control design (using prospec-
tive data with a mean follow-up time of 6 years for men and
7 years for women) and the sensitivity analyses excluding partici-
pants with baseline evidence of either MI or stroke reduce the pos-
sibility of the observed associations being due to reverse causality.
However, as this is an observational study, we cannot draw ﬁrm
conclusions about the causal role of IL-18 in development of stroke
or CHD. The degree of intra-individual variability in IL-18 levels
was measured 4 years apart was estimated using a regression dilu-
tion ratio, a considerable advantage over previous prospective
studies. The regression dilution ratio of 0.71, suggests similar sta-
bility of IL-18 to other established risk factors [15], the variability
in IL-18 levels means that estimates of the association between IL-
18 and CHD are likely to be conservative estimates of the true asso-
ciation. The sensitivity analyses, testing for differences by gender,
age and presence of pre-existing CVD showed similar results to
the main analyses but were less precise because of loss of statisti-
cal power due to smaller sample size.4.2. Baseline correlates of IL-18
The distribution of IL-18 observed in the men and women were
similar to the age-speciﬁc reference ranges reported for theGlasgowMONICA study, although median levels were slightly low-
er than in the younger Glasgow study population aged 55–64 years
[18]. Whereas the Glasgow study reported lower levels in women,
the present study found higher levels in women than in men at a
later age (60–79 years).
IL-18 was positively associated with established risk factors
blood pressure, HDL-cholesterol and BMI as seen in other studies
[18,19]. Not all previous studies [3,19] report associations between
IL-18 and total cholesterol and indeed we did not ﬁnd associations
between IL-18 and total cholesterol. IL-18 is reported to be posi-
tively associated with adiposity [19] and metabolic syndrome [7],
so the associations we observed in controls samples between IL-
18 and presence of pre-existing diabetes, BMI, glucose and insulin
levels were as expected. The associations seen between IL-18 and
other ‘‘downstream’’ inﬂammatory markers which are emerging
risk predictors (ﬁbrinogen, CRP, IL-6, white cell count, plasma vis-
cosity, vWF, Factor VIII, t-PA and D-dimer) were also positive, con-
ﬁrming other reports [18–20].4.3. IL-18 and risk of CHD
This study did not ﬁnd consistent evidence that IL-18 was inde-
pendently associated with risk of MI at conventional levels of sta-
tistical signiﬁcance. Only the age and sex adjusted estimates of the
association between continuous IL-18 and MI were statistically sig-
niﬁcant and associations were abolished on further adjustments,
this pattern is similar to three other prospective studies of CHD
which included men and women drawn from general populations
Table 4
Odds ratio (95%CI) of MI in men and women with IL-18 values in the higher tertiles compared to the lower tertile of the distribution (n = 895A).
IL-18 MI cases MI controls OR (95%CI) with adjustments
Tertiles Model 1b Model 2c Model 3c
Full sample n = 895
Range (pg/mL)
451–2500 113 199 1.31 (0.92, 1.85) 1.09 (0.75, 1.58) 1.05 (0.72, 1.53)
325–450 100 201 1.15 (0.81, 1.64) 1.13 (0.78, 1.64) 1.13 (0.78, 1.63)
10–324 86 196 1 1 1
Total 299 596 P = 0.130 p = 0.675 p = 0.829
Continuous 1 log2 (IL-18)B 299 596 1.34 (1.04, 1.72) 1.16 (0.88, 1.51) 1.09 (0.83, 1.44)
Sample excluding pre-existing CVD (n = 710)
Range (pg/mL)
451–2500 79 162 1.33 (0.89, 2.00) 1.12 (0.73, 1.73) 1.03 (0.66, 1.61)
325–450 70 170 1.15 (0.76, 1.73) 1.05 (0.68, 1.64) 1.14 (0.74, 1.76)
10–324 62 167 1 1 1
Total 211 499 P = 0.163 p = 0.831 p = 0.924
Continuous 1 log2 (IL-18)B 211 499 1.15 (0.94, 1.41) 1.02 (0.82, 1.27) 1.01 (0.81, 1.26)
Sample with pre-existing CVD (n = 185)
Range (pg/mL)
451–2500 34 37 1.04 (0.49, 2.18) 1.08 (0.49, 2.39) 1.07 (0.48, 2.39)
325–450 30 31 1.08 (0.49, 2.37) 1.15 (0.51, 2.63) 1.14 (0.50, 2.62)
10–324 24 29 1 1 1
Total 88 97 P = 0.945 p = 0.868 p = 0.902
Continuous 1 log2 (IL-18)B 88 97 1.01 (0.70, 1.47) 1.03 (0.70, 1.53) 1.03 (0.69, 1.53)
Model 1 = age, gender and region.
Model 2 = model 1 + SEP + smoking + alcohol + physical activity + history of diabetes + BMI + SBP + DBP + TC + HDL.
Model 3 = model 2 + logIL-6 + logCRP.
A Complete case analysis sample. Tertiles based on control group. P value for test for trend over tertiles.
B OR of MI per 1 log2 increase in log2(IL-18) i.e. doubling of IL-18.
Table 5
Odds ratio (95%CI) of stroke in men and women with IL-18 values in the higher tertiles compared to the lower tertile of the distribution (n = 727A).
IL-18 Stroke cases stroke controls OR (95%CI) with adjustments
Tertiles Model 1b Model 2c Model 3c
Full sample n = 727
Range (pg/mL)
455–2500 83 157 1.24 (0.84, 1.84) 1.07 (0.71, 1.61) 1.09 (0.72, 1.67)
330–454 82 169 1.14 (0.77, 1.68) 1.11 (0.73, 1.69) 1.07 (0.71, 1.61)
10–329 70 166 1 1 1
Total 235 492 P = 0.287 p = 0.626 p = 0.685
Continuous 1 log2 (IL-18)B 299 596 1.26 (0.84, 1.89) 1.13 (0.74, 1.74) 1.11 (0.72, 1.71)
Sample excluding pre-existing CVD (n = 594)
Range (pg/mL)
455–2500 54 132 1.11 (0.71, 1.75) 1.03 (0.64, 1.67) 1.02 (0.63, 1.64)
330–454 62 144 1.17 (0.75, 1.82) 1.09 (0.69, 1.73) 1.10 (0.70, 1.74)
10–329 54 148 1 1 1
Total 170 424 P = 0.640 p = 0.894 p = 0.949
Continuous 1 log2 (IL-18)B 170 424 1.03 (0.74, 1.44) 0.96 (0.67, 1.37) 0.94 (0.66, 1.35)
Sample with pre-existing CVD (n = 133)
Range (pg/mL)
455–2500 29 25 1.94 (0.37, 2.41) 1.94 (0.61, 6.13) 1.97 (0.62, 6.33)
330–454 20 25 1.50 (0.60, 3.72) 1.33 (0.44, 4.04) 1.35 (0.44, 4.16)
10–329 16 18 1 1 1
Total 65 68 P = 0.331 p = 0.246 p = 0.239
Continuous 1 log2 (IL-18)B 65 68 1.42 (0.82, 2.47) 1.73 (0.88, 3.42) 1.74 (0.88, 3.47)
Model 1 = age, gender and region.
Model 2 = model 1 + SEP + smoking + alcohol + physical activity + history of diabetes + BMI + SBP + DBP + TC + HDL.
Model 3 = model 2 + logIL-6 + logCRP.
A Complete case analysis sample. Tertiles based on control group. P value for test for trend over tertiles.
B OR of MI per 1 log2 increase in log2(IL-18) i.e. doubling of IL-18.
518 B.J. Jefferis et al. / Cytokine 61 (2013) 513–520
B.J. Jefferis et al. / Cytokine 61 (2013) 513–520 519where age and gender adjusted estimates were signiﬁcant, how-
ever further adjustment abolished the associations [19,21,22].
However, the conﬁdence intervals for our estimates of associations
between IL-18 and MI overlap with equivalent estimates from the
meta-analysis: OR CHD in BRHS/BWHHS 1.31 (95%CI 0.92, 1.85)
and OR CHD or CVD in meta-analysis 1.64 (95%CI 1.48, 1.83) [3].
The meta-analysis found statistically signiﬁcant associations be-
tween higher IL-18 and elevated risk of CHD, even after adjustment
for age, gender, established risk factors and inﬂammatory markers
IL-6 and CRP [3]. In addition, Mendelian randomization studies in
predominantly Caucasian, mostly male populations with average
age in mid 50 s or 60 s provide some support for a causal role of
IL-18 in risk of CAD or CVD [23,24]. The magnitude of the positive
association between continuous IL-18 and MI adjustment for age
and sex, in this study of 60–79 year old men and women, was sim-
ilar to the equivalent adjusted ORs reported in the cohort of men
when they were 20 years younger, adjustments for established
CVD risk factors and for CRP and IL-6 similarly abolished the asso-
ciations in both studies [3].
4.4. Associations between IL-18 and stroke
Few epidemiologic studies have investigated how IL-18 is asso-
ciated with risk of stroke, most evidence comes from studies with
composite CVD endpoints including stroke and CHD. The lack of
evidence for any elevated risk of stroke associated with IL-18 levels
in our study, is consistent with the three previous large studies. In
the HOPE study of patients with a history of CAD or stroke or dia-
betes, IL-18 was not associated with new stroke events during
4.5 years of follow-up [10], In the PROSPER trial, which recruited
patients with vascular risk factors or known vascular disease, there
was not evidence that IL-18 was associated with ischemic, hemor-
rhagic or total stroke over 3.2 years [9]. Similarly in a nested case-
control cohort of patients with a history of stroke in the PROGRESS
study which included patients with a history of stroke or transient
ischemic attack, IL-18 levels were not associated with recurrent
ischemic, hemorrhagic or total stroke events over 3.9 years of fol-
low-up [8]. However smaller case-control studies have docu-
mented raised IL-18 levels in the post-stroke period [25,26]. In
our study we had 80% power to detect a relative risk for stroke
of 1.79, assuming two controls per case, so it is possible that our
null results may be due to type two error, if the effects are in fact
smaller than 1.79, or if the association was diluted due to the mix
of both ischemic and hemorrhagic strokes in our study. Future, lar-
ger studies including mendelian randomization studies, with data
on sub-types of stroke may shed further light on any underlying
causal association.5. Conclusions
The results from this study do not support prospective indepen-
dent associations between IL-18 and risk of MI or stroke in older
men and women. The modest association with MI which is atten-
uated on adjustment for established and novel CHD risk factors,
may contribute to understanding the processes underlying risk of
MI.
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